Glooko and Innovation Zed Partner to Revolutionize Injectable Therapy Management with Digital Companion Apps
This innovative digital companion system, seamlessly integrating hardware and software, will be designed to integrate with the Glooko platform, currently used by over 8,200 diabetes clinics worldwide. This integration will enable the capture and analysis of critical information related to injectable therapies from the Innovation Zed DOSE platform technology, offering enhanced support for healthcare providers and patients alike.
U.S. FDA Grants Orphan Drug Designation to Ariceum Therapeutics’ Proprietary Radiopharmaceutical Cancer Therapy
Manfred Rüdiger, Chief Executive Officer at Ariceum Therapeutics, said: “Receiving ODD for 225Ac-satoreotide is a recognition of its potential as a treatment option for patients with SCLC and an important regulatory milestone for Ariceum. The FDA’s ODD will support our objective to accelerate the development of 225Ac-satoreotide through human trials to provide a potentially life-saving therapy to patients with limited alternatives.”
Implantica Announces Onboarding of the World-leading La Paz University Hospital, Spain
Dr. Peter Forsell, inventor of RefluxStop™, CEO and founder of Implantica, says, “Approximately 15% of the adult population in Spain suffer from GERD¹ with countless patients resigned to live with the painful symptoms because they are poorly treated by existing methods or not candidates for the mainstream anti-reflux surgical treatments.”
IBA signs Proteus®ONE system contract with AIG in Hyderabad, India
The contract includes the supply of a Proteus®ONE system and a Quality Assurance package from IBA Dosimetry. Proteus®ONE is the market leading compact proton therapy system, upgradable over time to continue to offer the latest technology to IBA users. The system will also include DynamicARC®[2] beam delivery capabilities, once this feature has received regulatory clearance.
Huxley Medical’s SANSA Home Sleep Apnea Test Gets FDA Nod

In a clinical trial involving 340 patients across seven institutions, SANSA obtained its initial FDA clearance in 2024, demonstrating its accuracy in comparison to the gold-standard polysomnography. This innovative test incorporates nine distinct physiological channels, such as oximetry, respiratory effort, sleep/wake staging, and a reference electrocardiogram (ECG), into a single patch worn on the chest. This integration allows for a comprehensive understanding of cardiopulmonary health and provides valuable insights.
Unveiling the Future of Neuropathy Treatment: NEUBIE Device Shows Remarkable Results
“Neuropathy is incredibly common among the aging population, regardless of disease states. There is currently no known cure for neuropathy, and most treatments address acute symptoms with no lasting impact,” says Dr. Ramona von Leden, VP of Research and Clinical Affairs for NeuFit. “NeuFit’s specialized approach to rehab focuses on supporting the function of the nervous system, and we are seeing remarkable results on patients with neuropathy.”
6 Career Pathways That Lead To Becoming A Doctor

Becoming a doctor is a long and difficult process that requires many years of schooling and training. But for those passionate about helping others, it can be the most rewarding career imaginable. Many pathways can lead to becoming a doctor, but all require hard work and dedication.
Fore Genomics Partners with Inocras to Launch Pediatric Genetic Health Screening and Newborn Sequencing
This partnership will blend Fore Genomics pediatric screening services with Inocras’s cutting-edge whole genome sequencing and bioinformatics platform, providing parents and healthcare providers with precise, personalized, and actionable insights into the genetic health of newborns and children, which can facilitate critical early diagnosis and proactive medical care.
Surmodics Announces Successful Early Clinical Use of Pounce™ XL Thrombectomy System, Suitable for Non-Surgical Removal of Thrombi and Emboli from Iliac and Femoral Arteries
“We’re excited about the positive feedback we’ve received from early users of the Pounce XL System,” said Gary Maharaj, President and Chief Executive Officer of Surmodics. “The addition of this larger-profile device to the Pounce Thrombectomy Platform fulfills our goal of providing physicians a standalone solution for rapid removal of acute or chronic peripheral arterial clot throughout the lower extremity. With hospitals under growing pressure to reduce costs, we believe the standalone Pounce Thrombectomy Platform may help reduce the need for hospitalizations and follow-up procedures.”
Rob Wojciechowski Named Chief Operations Officer of ELIQUENT Life Sciences
In this new role, Rob Wojciechowski will oversee the company’s strategic initiatives across its regulatory, quality, and compliance practice areas, further positioning ELIQUENT to meet the growing global demand for integrated regulatory, quality, and safety solutions across diverse markets.
RapidAI Secures FDA 510(k) Clearance for Groundbreaking AI 3D Head and Neck CTA Imaging: Lumina 3D™
RapidAI continues to pioneer AI advances by revolutionizing 3D imaging with no-click, AI-powered reconstruction.
The Role of Personalized Nutrition in Weight Loss Success

Personalized nutrition is becoming an essential approach for those looking to achieve sustainable weight loss. In recent years, there has been a growing awareness that one-size-fits-all diets are often not effective for everyone. Each person’s body reacts differently to food based on a variety of factors, including genetics, lifestyle, and health conditions. As a result, […]